Plasminogen is a joint-specific positive or negative determinant of arthritis pathogenesis in mice

Arthritis and Rheumatology

Volumn 66, Issue 6, 2014, Pages 1504-1516

  Raghu, Harini ^a   Jone, Alice ^a   Cruz, Carolina ^a   Rewerts, Cheryl L ^a   Frederick, Malinda D ^a   Thornton, Sherry ^a   Degen, Jay L ^a   Flick, Matthew J ^a  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; GELATINASE A; GELATINASE B; INTERLEUKIN 10; INTERLEUKIN 1BETA; INTERLEUKIN 6; PLASMINOGEN; RNA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY SCORE; DISEASE EXACERBATION; DISEASE SEVERITY; ENZYME ACTIVITY; EXPERIMENTAL ARTHRITIS; FIBRIN DEPOSITION; FIBRINOLYSIS; HISTOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; METACARPOPHALANGEAL JOINT; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHEUMATOID ARTHRITIS; RNA ISOLATION;

ANIMALS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; FEMALE; FIBRINOGEN; JOINTS; MALE; MATRIX METALLOPROTEINASE 9; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MICE, TRANSGENIC; PLASMINOGEN; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84901067795     PISSN: 23265191     EISSN: 23265205     Source Type: Journal    
DOI: 10.1002/art.38402     Document Type: Article

References (48)

1. Helmick CG, Felson DT, Lawrence RC, Gabriel S, Hirsch R, Kwoh CK, et al, for the National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States: part I. Arthritis Rheum 2008; 58: 15-25.
2. Abdel-Nasser AM, Rasker JJ, Valkenburg HA,. Epidemiological and clinical aspects relating to the variability of rheumatoid arthritis. Semin Arthritis Rheum 1997; 27: 123-40.
3. Alamanos Y, Voulgari PV, Drosos AA,. Incidence and prevalence of rheumatoid arthritis, based on the 1987 American College of Rheumatology criteria: a systematic review. Semin Arthritis Rheum 2006; 36: 182-8.
4. Yang YH, Carmeliet P, Hamilton JA,. Tissue-type plasminogen activator deficiency exacerbates arthritis. J Immunol 2001; 167: 1047-52.
5. Marty I, Peclat V, Kirdaite G, Salvi R, So A, Busso N,. Amelioration of collagen-induced arthritis by thrombin inhibition. J Clin Invest 2001; 107: 631-40.
6. 2 binding motif. J Clin Invest 2007; 117: 3224-35.
7. So AK, Varisco PA, Kemkes-Matthes B, Herkenne-Morard C, Chobaz-Peclat V, Gerster JC, et al. Arthritis is linked to local and systemic activation of coagulation and fibrinolysis pathways. J Thromb Haemost 2003; 1: 2510-5.
8. Busso N, Peclat V, Van Ness K, Kolodziesczyk E, Degen J, Bugge T, et al. Exacerbation of antigen-induced arthritis in urokinase-deficient mice. J Clin Invest 1998; 102: 41-50.
9. Cook AD, Braine EL, Campbell IK, Hamilton JA,. Differing roles for urokinase and tissue-type plasminogen activator in collagen-induced arthritis. Am J Pathol 2002; 160: 917-26.
10. Cook AD, De Nardo CM, Braine EL, Turner AL, Vlahos R, Way KJ, et al. Urokinase-type plasminogen activator and arthritis progression: role in systemic disease with immune complex involvement. Arthritis Res Ther 2010; 12: R37.
11. De Nardo CM, Lenzo JC, Pobjoy J, Hamilton JA, Cook AD,. Urokinase-type plasminogen activator and arthritis progression: contrasting roles in systemic and monoarticular arthritis models. Arthritis Res Ther 2010; 12: R199.
12. Busso N, Hamilton JA,. Extravascular coagulation and the plasminogen activator/plasmin system in rheumatoid arthritis [review]. Arthritis Rheum 2002; 46: 2268-79.
13. Flick MJ, Chauhan AK, Frederick M, Talmage KE, Kombrinck KW, Miller W, et al. The development of inflammatory joint disease is attenuated in mice expressing the anticoagulant prothrombin mutant W215A/E217A. Blood 2011; 117: 6326-37.
14. Tetta C, Camussi G, Modena V, Di Vittorio C, Baglioni C,. Tumour necrosis factor in serum and synovial fluid of patients with active and severe rheumatoid arthritis. Ann Rheum Dis 1990; 49: 665-7.
15. Ji H, Pettit A, Ohmura K, Ortiz-Lopez A, Duchatelle V, Degott C, et al. Critical roles for interleukin 1 and tumor necrosis factor α in antibody-induced arthritis. J Exp Med 2002; 196: 77-85.
16. Williams RO, Feldmann M, Maini RN,. Anti-tumor necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc Natl Acad Sci U S A 1992; 89: 9784-8.
17. Piguet PF, Grau GE, Vesin C, Loetscher H, Gentz R, Lesslauer W,. Evolution of collagen arthritis in mice is arrested by treatment with anti-tumour necrosis factor (TNF) antibody or a recombinant soluble TNF receptor. Immunology 1992; 77: 510-4.
18. Lewthwaite J, Blake S, Hardingham T, Foulkes R, Stephens S, Chaplin L, et al. Role of TNFα in the induction of antigen induced arthritis in the rabbit and the anti-arthritic effect of species specific TNFα neutralising monoclonal antibodies. Ann Rheum Dis 1995; 54: 366-74.
19. Probert L, Akassoglou K, Alexopoulou L, Douni E, Haralambous S, Hill S, et al. Dissection of the pathologies induced by transmembrane and wild-type tumor necrosis factor in transgenic mice. J Leukoc Biol 1996; 59: 518-25.
20. Alexopoulou L, Pasparakis M, Kollias G,. A murine transmembrane tumor necrosis factor (TNF) transgene induces arthritis by cooperative p55/p75 TNF receptor signaling. Eur J Immunol 1997; 27: 2588-92.
21. Keffer J, Probert L, Cazlaris H, Georgopoulos S, Kaslaris E, Kioussis D, et al. Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. EMBO J 1991; 10: 4025-31.
22. Bugge TH, Flick MJ, Daugherty CC, Degen JL,. Plasminogen deficiency causes severe thrombosis but is compatible with development and reproduction. Genes Dev 1995; 9: 794-807.
23. Bugge TH, Kombrinck KW, Flick MJ, Daugherty CC, Danton MJ, Degen JL,. Loss of fibrinogen rescues mice from the pleiotropic effects of plasminogen deficiency. Cell 1996; 87: 709-19.
24. Sullivan BP, Kassel KM, Jone A, Flick MJ, Luyendyk JP,. Fibrin(ogen)-independent role of plasminogen activators in acetaminophen-induced liver injury. Am J Pathol 2012; 180: 2321-9.
25. Li P, Schwarz EM,. The TNF-α transgenic mouse model of inflammatory arthritis. Springer Semin Immunopathol 2003; 25: 19-33.
26. Busso N, Peclat V, So A, Sappino AP,. Plasminogen activation in synovial tissues: differences between normal, osteoarthritis, and rheumatoid arthritis joints. Ann Rheum Dis 1997; 56: 550-7.
27. Bezerra JA, Bugge TH, Melin-Aldana H, Sabla G, Kombrinck KW, Witte DP, et al. Plasminogen deficiency leads to impaired remodeling after a toxic injury to the liver. Proc Natl Acad Sci U S A 1999; 96: 15143-8.
28. Ng VL, Sabla GE, Melin-Aldana H, Kelley-Loughnane N, Degen JL, Bezerra JA,. Plasminogen deficiency results in poor clearance of non-fibrin matrix and persistent activation of hepatic stellate cells after an acute injury. J Hepatol 2001; 35: 781-9.
29. Tsirka SE, Bugge TH, Degen JL, Strickland S,. Neuronal death in the central nervous system demonstrates a non-fibrin substrate for plasmin. Proc Natl Acad Sci U S A 1997; 94: 9779-81.
30. Plows D, Kontogeorgos G, Kollias G,. Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. J Immunol 1999; 162: 1018-23.
31. Itoh T, Matsuda H, Tanioka M, Kuwabara K, Itohara S, Suzuki R,. The role of matrix metalloproteinase-2 and matrix metalloproteinase-9 in antibody-induced arthritis. J Immunol 2002; 169: 2643-7.
32. Firestein GS, Budd RC, Gabriel SE, McInnes IB, O'Dell JR, editors. Kelley's textbook of rheumatology. 9th ed. Philadelphia: Elsevier/Saunders; 2013.
33. Wallberg-Jonsson S, Rantapaa-Dahlqvist S, Nordmark L, Ranby M,. Mobilization of fibrinolytic enzymes in synovial fluid and plasma of rheumatoid arthritis and spondyloarthropathy and their relation to radiological destruction. J Rheumatol 1996; 23: 1704-9.
34. Slot O, Brunner N, Locht H, Oxholm P, Stephens RW,. Soluble urokinase plasminogen activator receptor in plasma of patients with inflammatory rheumatic disorders: increased concentrations in rheumatoid arthritis. Ann Rheum Dis 1999; 58: 488-92.
35. Li J, Ny A, Leonardsson G, Nandakumar KS, Holmdahl R, Ny T,. The plasminogen activator/plasmin system is essential for development of the joint inflammatory phase of collagen type II-induced arthritis. Am J Pathol 2005; 166: 783-92.
36. Valentino LA,. Blood-induced joint disease: the pathophysiology of hemophilic arthropathy. J Thromb Haemost 2010; 8: 1895-902.
37. Norian JM, Ries MD, Karp S, Hambleton J,. Total knee arthroplasty in hemophilic arthropathy. J Bone Joint Surg Am 2002; 84-A: 1138-41.
38. Lijnen HR, Van Hoef B, Lupu F, Moons L, Carmeliet P, Collen D,. Function of the plasminogen/plasmin and matrix metalloproteinase systems after vascular injury in mice with targeted inactivation of fibrinolytic system genes. Arterioscler Thromb Vasc Biol 1998; 18: 1035-45.
39. Carmeliet P, Moons L, Lijnen R, Baes M, Lemaitre V, Tipping P, et al. Urokinase-generated plasmin activates matrix metalloproteinases during aneurysm formation. Nat Genet 1997; 17: 439-44.
40. Gong Y, Hart E, Shchurin A, Hoover-Plow J,. Inflammatory macrophage migration requires MMP-9 activation by plasminogen in mice. J Clin Invest 2008; 118: 3012-24.
41. Lijnen HR,. Plasmin and matrix metalloproteinases in vascular remodeling. Thromb Haemost 2001; 86: 324-33.
42. Lund LR, Romer J, Bugge TH, Nielsen BS, Frandsen TL, Degen JL, et al. Functional overlap between two classes of matrix-degrading proteases in wound healing. EMBO J 1999; 18: 4645-56.
43. Liu Z, Li N, Diaz LA, Shipley M, Senior RM, Werb Z,. Synergy between a plasminogen cascade and MMP-9 in autoimmune disease. J Clin Invest 2005; 115: 879-87.
44. Castaneda FE, Walia B, Vijay-Kumar M, Patel NR, Roser S, Kolachala VL, et al. Targeted deletion of metalloproteinase 9 attenuates experimental colitis in mice: central role of epithelial-derived MMP. Gastroenterology 2005; 129: 1991-2008.
45. Lighvani S, Baik N, Diggs JE, Khaldoyanidi S, Parmer RJ, Miles LA,. Regulation of macrophage migration by a novel plasminogen receptor Plg-R KT. Blood 2011; 118: 5622-30.
46. Miles LA, Lighvani S, Baik N, Andronicos NM, Chen EI, Parmer CM, et al. The plasminogen receptor, Plg-R(KT), and macrophage function. J Biomed Biotechnol 2012; 2012: 250464.
47. Miles LA, Dahlberg CM, Plescia J, Felez J, Kato K, Plow EF,. Role of cell-surface lysines in plasminogen binding to cells: identification of α-enolase as a candidate plasminogen receptor. Biochemistry 1991; 30: 1682-91.
48. Kim J, Hajjar KA,. Annexin II: a plasminogen-plasminogen activator co-receptor. Front Biosci 2002; 7: d341-8.